DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Asciminib is an investigational drug.
There have been 12 clinical trials for Asciminib. The most recent clinical trial was a Phase 1 trial, which was initiated on October 13th 2021.
The most common disease conditions in clinical trials are Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Novartis Pharmaceuticals, Ludwig-Maximilians - University of Munich, and Prof. Dr. med. Andreas Hochhaus.
There are three US patents protecting this investigational drug and eighty-nine international patents.
Recent Clinical Trials for Asciminib
|Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors||Novartis Pharmaceuticals||Phase 2|
|Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia||Novartis Pharmaceuticals||Phase 1/Phase 2|
|Asciminib Roll-over Study||Novartis Pharmaceuticals||Phase 3|
Top disease conditions for Asciminib
Top clinical trial sponsors for Asciminib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Asciminib||⤷ Try it Free||Antibody molecules to PD-L1 and methods of treating cancer||Novartis AG (Basel, CH) Dana-Farber Cancer Institute, Inc. (Boston, MA) President and Fellows of Harvard College (Cambridge, MA)||⤷ Try it Free|
|Asciminib||⤷ Try it Free||Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1||Novartis AG (Basel, CH)||⤷ Try it Free|
|Asciminib||⤷ Try it Free||Antibody molecules to PD-L1 and uses thereof||Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Asciminib||Argentina||AR104081||2034-10-14||⤷ Try it Free|
|Asciminib||Australia||AU2015333687||2034-10-14||⤷ Try it Free|
|Asciminib||Brazil||BR112017007379||2034-10-14||⤷ Try it Free|
|Asciminib||Canada||CA2964367||2034-10-14||⤷ Try it Free|
|Asciminib||Chile||CL2017000888||2034-10-14||⤷ Try it Free|
|Asciminib||China||CN107001478||2034-10-14||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|